Isopropylphenidate

Uncontrolled hypertension, Cardiac arrhythmias, Structural heart disease, Recent myocardial infarction

Isopropylphenidate's sympathomimetic action increases heart rate and blood pressure. Patients with severe cardiovascular disease, including uncontrolled hypertension, arrhythmias, structural heart disease, or recent myocardial infarction, face elevated risk of acute cardiovascular events.

High-dose stimulant use can lower seizure threshold. Individuals with epilepsy or other seizure disorders face increased risk. Risk is dose-dependent and more pronounced at supratherapeutic doses.

DAT inhibition increases synaptic dopamine in mesolimbic circuits. In individuals with active psychosis or psychotic disorders, this dopaminergic potentiation can trigger or exacerbate hallucinations, delusions, and paranoid ideation.

Dopaminergic and noradrenergic stimulation can worsen anxiety symptoms. While IPH's reduced NET activity may produce less anxiogenic effect than methylphenidate, stimulant-class anxiogenesis remains a concern.

As a DAT reuptake inhibitor, isopropylphenidate has intrinsic abuse liability. Individuals with a history of substance use disorders face elevated risk of compulsive use, dose escalation, and psychological dependence. Compulsive redosing urge is a notable feature reported by users, particularly via insufflation.

Hyperthyroidism produces a baseline sympathomimetic state. Adding a DAT/NET reuptake inhibitor compounds cardiovascular strain (tachycardia, hypertension) and metabolic effects.

Sympathomimetic stimulants can cause pupil dilation, increasing intraocular pressure. Individuals with narrow-angle glaucoma or predisposition to angle-closure are at risk of acute glaucoma episodes.

Concurrent use of monoamine oxidase inhibitors (MAOIs) with isopropylphenidate carries risk of hypertensive crisis and serotonin syndrome. This is a standard class contraindication for all DAT/NET reuptake inhibitors. No IPH-specific MAOI interaction data exist.